Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 892 participants.

Also called NCT04807400

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose health services research
Phase
Phase 3
Enrolled
  • 892 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04807400
  • EudraCT 2020-004401-31
Other papers using this trial's data
  • Development and application of a qualitative rapid analysis framework in a hybrid trial within primary care BMJ open, 2024-07-24 DOI, PubMed 39053958, PMC11284935 In the PMC Open Access subset under CC BY.
  • Evaluating the implementation of inclisiran in primary care: process evaluation interim findings from interviews with key stakeholders BMJ open, 2025-02-26 DOI, PubMed 40010816, PMC11865805 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04807400. Randomized; no masking; primary purpose health services research. Start 2021-07-07 (actual); primary completion 2023-01-13 (actual). Results posted on 2024-03-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support
Acronym
SPIRIT
Condition
Atherosclerotic Cardiovascular Disease
Condition
Atherosclerotic Cardiovascular Disease Risk Equivelents
Condition
Elevated Low Density Lipoprotein Cholesterol
Intervention (Drug)
Inclisiran
Intervention (Behavioral)
Behavioural Support
Intervention (Drug)
Background lipid lowering therapy
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04807400
Content hash
f210b64b104a092a0bea25f4d0a68dee4111dea6b5ce6510fb42b9f0626baf50